Clinical trials: Hemostasis
Multiple Myeloma
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma.
- Trial name
- NCT02863991
- Testing
- ONC201, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Myeloma
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
The purpose of this study is to test the safety and efficacy of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.
- Trial name
- APRIL (NCT03287804)
- Testing
- AUTO2
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Autolus Limited
Multiple Myeloma
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade®…
- Trial name
- CLARION (NCT01818752)
- Testing
- Carfilzomib, Bortezomib, Melphalan
- Where
- 213 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth…
- Trial name
- NCT00523848
- Testing
- bortezomib, pegylated liposomal doxorubicin hydrochloride, thalidomide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Roswell Park Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as…
- Trial name
- NCT01421186
- Testing
- MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone
- Where
- 10 sites in Austria, Germany
- Volunteers
- 91 people
- Sponsor
- MorphoSys AG
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Peripheral Vascular Disease, Hemorrhage
The Evicel Post-Authorization Surveillance Study
The objective of this non-interventional Post Authorisation Safety Surveillance (PASS) study is to observe the clinical safety performance of EVICEL when used as suture support for haemostasis in vascular surgery.
- Trial name
- NCT01158261
- Testing
- EVICEL ™ Fibrin Sealant (Human)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Ethicon, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. It is not yet known whether combining thalidomide with prednisone and giving them after autologous stem cell transplantation may…
- Trial name
- NCT00049673
- Testing
- prednisone, thalidomide
- Where
- 18 sites in Canada
- Volunteers
- 332 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Chemotherapeutic Agent Toxicity, Multiple Myeloma
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib.
- Conditions
- Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
- Trial name
- NCT01783522
- Testing
- glutamine, quality-of-life assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Faiman
Lymphoma, Mantle Cell Lymphoma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either…
- Conditions
- Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
- Trial name
- VCR (NCT00980395)
- Testing
- rituximab, bortezomib, cladribine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Multiple Myeloma
A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma
Randomized, open-label, international, multi-center, Phase 3 study in which patients are randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.
- Trial name
- NCT00722566
- Testing
- VELCADE Administered by subcutaneous injection, VELCADE Administered by intravenous infusion
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 222 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Multiple Myeloma
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.
- Trial name
- NCT01179490
- Testing
- SyB L-0501, prednisolone
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- SymBio Pharmaceuticals
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Thrombosis
Heart and Hands Study II: A Retrospective Data Collection & Analysis Project
A recent pilot study conducted at HealthEast found use of manual pressure with the SoftSeal hemostatic pad for 15 minutes was successful in 9 out of 10 people fully anticoagluated using 4 French radial sheath.
- Trial name
- NCT02307318
- Testing
- SoftSeal Hemostatic Pad
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- HealthEast Care System
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well donor peripheral blood stem cell (PBSC) transplant works in treating patients with hematologic malignancies.
- Conditions
- Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01028716
- Testing
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
This pilot study of scalp cooling with Penguin cold caps will examine the effectiveness of scalp cooling to reduce the development of hair loss in 30 participants with multiple myeloma undergoing high-dose chemotherapy with…
- Trial name
- NCT05961215
- Testing
- Penguin Cold Cap
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Cedars-Sinai Medical Center
Multiple Myeloma
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
The primary goal of this study is to determine the feasibility and safety of giving two doses of denileukin diftitox (DD) at days 0 and 21 post autologous stem cell transplantation in a dose escalation fashion.
- Trial name
- NCT01251952
- Testing
- Denileukin Diftitox (Ontak)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.